Smallpox - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Smallpox - Pipeline Review, H2 2016

Smallpox - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Smallpox - Pipeline Review, H2 2016
Published Jul 13, 2016
84 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Smallpox - Pipeline Review, H2 2016, provides an overview of the Smallpox pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
- The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying

  
Source:
Document ID
GMDHC8275IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Smallpox Overview71
Therapeutics Development82
  Pipeline Products for Smallpox Overview81
  Pipeline Products for Smallpox Comparative Analysis91
Smallpox Therapeutics under Development by Companies101
Smallpox Therapeutics under Investigation by Universities/Institutes111
Smallpox Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Smallpox Products under Development by Companies141
Smallpox Products under Investigation by Universities/Institutes151
Smallpox Companies Involved in Therapeutics Development169
  Bavarian Nordic A/S161
  BioFactura, Inc.171
  CEL-SCI Corporation181
  Chimerix, Inc.191
  CJ HealthCare Corp.201
  EpiVax, Inc.211
  SIGA Technologies, Inc.221
  Takeda Pharmaceutical Company Limited231
  Tonix Pharmaceuticals Holding Corp.241
Smallpox Therapeutics Assessment2510
  Assessment by Monotherapy Products251
  Assessment by Combination Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3536
  (plague + small pox) vaccine Drug Profile351
  24a Drug Profile361
  brincidofovir Drug Profile3713
  CEL-1000 Drug Profile502
  CJ-40011 Drug Profile521
  imatinib mesylate Drug Profile531
  Monoclonal Antibodies for Infectious Disease Drug Profile541
  Monoclonal Antibody for Smallpox Drug Profile551
  nilotinib Drug Profile561
  PL-801 Drug Profile571
  SCV-305 Drug Profile581
  small pox vaccine Drug Profile591
  smallpox vaccine Drug Profile604
  smallpox vaccine Drug Profile641
  tecovirimat Drug Profile655
  VIR-002 Drug Profile701
Smallpox Dormant Projects712
Smallpox Discontinued Products731
Smallpox Product Development Milestones749
  Featured News &Press Releases741
    Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government741
    Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA s Tecovirimat Antiviral741
    Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox741
    Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene751
    Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox751
    Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox761
    Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million761
    May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine771
    Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery781
    Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess ...781
    Dec 23, 2014: Chimerix Provides Recap of 2014 Events791
    Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine801
    Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine801
    Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox811
    Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine812
Appendix832
  Methodology831
  Coverage831
  Secondary Research831
  Primary Research831
  Expert Panel Validation831
  Contact Us831
  Disclaimer841

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Smallpox - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Smallpox-Pipeline-Review-H2-2016-2088-16176>
  
APA:
Global Markets Direct - Market Research. (2016). Smallpox - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Smallpox-Pipeline-Review-H2-2016-2088-16176>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.